Pharmacotherapy options for advanced renal cell carcinoma

Bibliography

• Ong KR, Woodward ER, Killick P, et al. Genotype-phenotype correlations in von Hippel Lindau disease. Hum Mutat 2007;28:143-9
   PubMed Web of Science ®Google Scholar
• Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 2009;9:231-41
   PubMed Web of Science ®Google Scholar
• Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-MET signaling pathway in renal cell carcinoma. Cancer J 2013;19:316-23
   PubMed Web of Science ®Google Scholar
• Pal SK, Williams S, Josephson DY, et al. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 2012;11:526-37
   PubMed Web of Science ®Google Scholar
• Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006;24:3101-6
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013;108:2470-7
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9
   PubMed Web of Science ®Google Scholar
• Hamano K, Esumi M, Igarashi H, et al. Biallelic inactivation of the Von-Hippel Lindau tumor suppressor gene in sporadic renal cell carcinoma. J Urol 2002;167:713-17
   PubMed Web of Science ®Google Scholar
• Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013;23(1):18-25
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet 2013;14:552-62
   Web of Science ®Google Scholar
• Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14(13):1287-94
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 2014, doi:10.1200/JCO.2013.50.8267
   Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31(30):3791-9
   PubMed Web of Science ®Google Scholar
• Angevin E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013;19:1257-68
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Szczylik C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15(3):286-96
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10(8):757-63
   PubMed Web of Science ®Google Scholar
• Lee JL, Park I, Park K, et al. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. J Cancer Res Clin Oncol 2012;138(4):687-93
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:1287-96
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Patients preference between pazopanib and sunitinib: results of a randomized double-blind, placebo-controlled, cross over study in patients with metastatic renal cell carcinoma (mRCC)_PISCES study. J Clin Oncol 2012;30(Suppl):abstract CRA4502
   Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma(AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-50
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-43
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Global ARCC trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2006;19:1387-92
   Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. 2013. Available from: http://www.clinicaltrials.gov/
   Google Scholar
• Choueiri T, Kumar Pal S, McDermott DF, et al. Efficacy of cabozantinib (XL184) in patients with metastatic, refractory renal cell carcinoma. J Clin Oncol 2012;30(Suppl):abstract 4504
   Google Scholar
• Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma subjects: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004;101:17174-9
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death -1 in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75
   PubMed Web of Science ®Google Scholar
• McDermott DF, Drake CG, Sznol M, et al. Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MXD-1106/ONO-4538) in patients with previously treated, metastatic renal cell carcinoma: an updated analysis. J Clin Oncol 2013;31(Suppl 6):abstract 351
   Web of Science ®Google Scholar
• Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011;12:1143-50
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2013;108:887-900
   PubMed Web of Science ®Google Scholar
• Dornbusch J, Zacharis A, Meinhardt M, et al. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One 2013;8:1-11
   Web of Science ®Google Scholar
• Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011;29:2557-64
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763-73
   PubMed Web of Science ®Google Scholar
• Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17:3841-9
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011;117:534-44
   PubMed Web of Science ®Google Scholar
• Lee CK, Marschner I, Simes J, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012;18(11):3188-96
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31(Suppl):abstract 4504
   Google Scholar
• Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007;13:5232-7
   PubMed Web of Science ®Google Scholar
• Feldman DR, Baum MS, Ginsberg ME, et al. Phase I trial of bevacizumab plus escalated dose of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-9
   PubMed Web of Science ®Google Scholar
• Negrier S, Imbs CI, Pérol D, et al. Pazopanib and bevacizumab in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: phase I combination study final analysis. J Clin Oncol 2013;31(Suppl):abstract 4574
   Google Scholar
• Hutson TE, Bukowski RM, Sternberg CN, et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2011;77:48-62
   PubMed Web of Science ®Google Scholar
• Michel MS, Vervenne W, De Santis M, et al. SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib(SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). J Clin Oncol 2014;32(Suppl 4):abstract 393
   Web of Science ®Google Scholar
• Eichelberg C, Heuer R, Chun FK, et al. Sequential use of tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:1373-8
   PubMed Web of Science ®Google Scholar
• McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014;65(3):577-84
   PubMed Web of Science ®Google Scholar